Navigation Links
One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
Date:5/15/2012

NATICK, Mass., May 15, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in treating de novo coronary artery lesions at one year compared to the PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent System in the EVOLVE First Human Use Trial.  The trial reported one-year clinical and six-month intravascular ultrasound (IVUS) outcomes data, evaluating the safety and effectiveness of the bioabsorbable abluminal polymer-coated SYNERGY Stent.  Results were presented today at the annual EuroPCR Scientific Program in Paris by Stefan Verheye, M.D., Ph.D., F.E.S.C., senior interventional cardiologist at the Antwerp Cardiovascular Institute, ZNA Middelheim Hospital, Belgium.

The EVOLVE trial previously reported the primary angiographic and clinical endpoints of non-inferiority of the SYNERGY Stent compared with PROMUS Element for late loss at 6 months and target lesion failure (TLF) at 30 days.  The EVOLVE one-year trial data demonstrated that both versions of the SYNERGY Stent (loaded with both full- and half-dose everolimus) are clinically non-inferior to the PROMUS Element Stent.  There were no significant differences between groups for all IVUS parameters evaluated at 6 months, including neointimal area, stent or lumen area, net volume obstruction, incomplete stent apposition or minimum lumen diameter.

"The 6-month IVUS data suggest that anti-restenotic activity is maintained with the SYNERGY stent, even after four months, when the drug and polymer coating are designed to be absorbed. Importantly, the SYNERGY Stent has shown equivalent clinical safety and effectiveness in the EVOLVE data compared to the PROMUS Element Stent.  We continue to observe very low rate
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohns Disease
6. Diabetes Conversation Map(TM) Education Tools Celebrate One-Year Anniversary
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. One-Year European Registry Data Released for Popliteal Stenting With SUPERA®
9. Former NxStage System One User Celebrates One-Year Kidney Transplant Anniversary
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Elekta VMAT Radiation Therapy Rapidly Gaining Users Worldwide as Technique Evolves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:9/4/2015)... ... September 04, 2015 , ... ... technology is now available at CitiDent. CEREC is a newer method for creating ... saving time for patients by eliminating the need for multiple appointments, CEREC produces ...
(Date:9/4/2015)... ... ... looking for a quick and convenient way to produce a hot remedy for colds. The ... quick and simple way to brew a hot cup of cold remedy when desired. In ... enhance comfort and health. The invention features a novel design that is lightweight, compact and ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference program for the ... October 9-10, 2015 at the Diplomat Resort & Spa has been announced and ... researchers at the top of their field and will be presenting sessions such ...
(Date:9/4/2015)... York, NY (PRWEB) , ... September 04, 2015 , ... ... meters qualifying heat, and followed up with victory in the men’s 400 meters final, ... (NACAC) Senior Track and Field Championships in San Jose, Costa Rica in August 2015. ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... says are prophetic details involving the Pope’s upcoming trip to the United States. , Yisrayl ... what his role with the Vatican and society is. Yisrayl also provides the meaning of ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... Package Provided in NDA Demonstrates ... Tramadol Formulation, LAVAL, QC, Sept. 24 /PRNewswire-FirstCall/ - ... has requested a meeting with the U.S.,Food and Drug ... its once-daily formulation of tramadol. Based on,additional analysis that ...
... Sept. 24 Sister Carol Keehan,DC, president and ... the United States (CHA), issued the following statement. ... compromise to,reauthorize the State Children,s Health Insurance Program ... the legislation. Reauthorizing SCHIP represents the most ...
... need to look beyond the renal arteries when doing renal ... in Rochester, MN suggests. The study found that 98% ... additional vascular or nonvascular findings. , The study included 380 ... 151 (40%) of these patients had one or more additional ...
... future,missions to the moon and Mars could face serious ... National Space Biomedical Research,Institute, known as NSBRI, Houston, will ... better understand and reduce those risks. Scientists at,universities, research ... studies. The goal of NASA,s space radiation research ...
... finds real improvements compared to standard therapy , MONDAY, ... Chinese or even sham acupuncture treatment appeared more effective ... German study of almost 1,200 patients. , Traditional ... points on the body to a depth of 5 ...
... Offer Retirement Solution to Large Corporations, NEW ... announced today that it has hired Bill McDermott ... also been named a member of the,company,s Executive ... retirement solutions for Fortune 1000 companies. The,announcement was ...
Cached Medicine News:Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 2Health News:Labopharm provides update on U.S. regulatory process for once-daily Tramadol 3Health News:Catholic Health Association to Congress and President Bush: Uninsured Children Need Your Help Now 2Health News:NASA, NSBRI Select 17 Proposals in Space Radiation Research 2Health News:Even Sham Acupuncture Eases Low Back Pain 2Health News:AXA Equitable Life Insurance Co. Hires William McDermott to Lead Corporate Retirement Planning Business 2Health News:AXA Equitable Life Insurance Co. Hires William McDermott to Lead Corporate Retirement Planning Business 3
... secondary condenser to trap residual solvent vapors ... vacuum pump designed to handle most vacuum ... for use with up to two rotary ... instruments including vacuum ovens, concentrators, gel dryers, ...
... System UVS400A is a multi-tasking vacuum source ... a refrigerated vapor trap and a maintenance-free, ... unit. The easy-to-use, wide-mouth glass condensation flask ... jar for easy disposal. The UVS400A provides ...
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)...
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)...
Medicine Products: